INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 412m ago
HOUSE PTR11m ago
SEC 13F11m ago
ROBINHOOD CHAIN11m ago
SEC FORM 4/Grant or awardVerified data

Fitzpatrick Jennifer reported SION

Chief Legal Officer · Sionna Therapeutics, Inc. · Sionna Therapeutics, Inc. — Non-Qualified Stock Option (right to buy)

Side
A
Value
—
Shares
103.1K
Price
—
Executed
Jan 2, 2026
Disclosed
Jan 6, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 2 executedJan 6, 2026 disclosed

SION · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
5/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SION

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    CM
    Cloonan MichaelDirector, President & CEO
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    109.0K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CM
    Cloonan MichaelDirector, President & CEO
    SIONSionna Therapeutics, Inc.
    Disposition to issuer
    		D—
    436.1K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    17
    FJ
    Fitzpatrick JenniferCLO and Head of Program Mgmt.
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    28.1K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RE
    Ridloff ElenaCFO and CBO
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    165.4K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    5
    FJ
    Fitzpatrick JenniferCLO and Head of Program Mgmt.
    SIONSionna Therapeutics, Inc.
    Disposition to issuer
    		D—
    103.1K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    21
    RE
    Ridloff ElenaCFO and CBO
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    47.3K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    21
    RE
    Ridloff ElenaCFO and CBO
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    47.3K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    9
    CM
    Cloonan MichaelDirector, President & CEO
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    436.1K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MC
    McKee CharlotteCMO and Head of R&D
    SIONSionna Therapeutics, Inc.
    Disposition to issuer
    		D—
    155.7K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MC
    McKee CharlotteCMO and Head of R&D
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    155.7K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    5
    FJ
    Fitzpatrick JenniferCLO and Head of Program Mgmt.
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    28.1K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    21
    MC
    McKee CharlotteCMO and Head of R&D
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    50.0K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    13
    CM
    Cloonan MichaelDirector, President & CEO
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    109.0K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    21
    MC
    McKee CharlotteCMO and Head of R&D
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    50.0K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    5
    FJ
    Fitzpatrick JenniferCLO and Head of Program Mgmt.
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    103.1K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    9
    RE
    Ridloff ElenaCFO and CBO
    SIONSionna Therapeutics, Inc.
    Disposition to issuer
    		D—
    165.4K sh
    		Sep 17, 2026Sep 18, 2026
    traded Sep 17, 2026
    		+1dSEC FORM 4

    Evidence

    0
    FJ
    Fitzpatrick JenniferChief Legal Officer
    SIONSionna Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$63K
    10.3K sh
    		Jul 6, 2026Jul 7, 2026
    traded Jul 6, 2026
    		+1dSEC FORM 4

    Evidence

    19
    FJ
    Fitzpatrick JenniferChief Legal Officer
    SIONSionna Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$447K
    10.3K sh
    		Jul 6, 2026Jul 7, 2026
    traded Jul 6, 2026
    		+1dSEC FORM 4

    Evidence

    3
    FJ
    Fitzpatrick JenniferChief Legal Officer
    SIONSionna Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    10.3K sh
    		Jul 6, 2026Jul 7, 2026
    traded Jul 6, 2026
    		+1dSEC FORM 4

    Evidence

    9
    FE
    Fleming Harold EdwardDirector
    SIONSionna Therapeutics, Inc.
    Grant or award
    		A—
    17.3K sh
    		Jun 17, 2026Jun 18, 2026
    traded Jun 17, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002061851-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 2, 2026
    Published
    Jan 6, 2026
    Ingested by INSIDER
    Nov 5, 04:24 UTC
    Last re-read
    Nov 5, 04:24 UTC

    Extracted facts

    Filer
    Fitzpatrick Jennifer
    Role
    Chief Legal Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Sionna Therapeutics, Inc. — Non-Qualified Stock Option (right to buy)
    Ticker
    SION
    Shares
    103.1K
    Price per share
    $0
    Execution date (reported)
    Jan 2, 2026
    Owned after transaction
    103.1K shares
    Days from execution to publication
    4

    What this establishes

    Fitzpatrick Jennifer filed this Form 4 reporting a grant or award of SION on Jan 2, 2026. It became public on Jan 6, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Legal Officer
    Fitzpatrick Jennifercik:0002061851
    Issuer
    Sionna Therapeutics, Inc.cik:0002036042

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.